by North Woods | Jun 23, 2026 | Blog, Firm News
MADISON, Wis., June 23, 2026 — Clarevia Ventures today announced the appointment of Margaret Kaczor Andrew as Venture Partner. In this role, Kaczor Andrew will focus on sourcing, evaluating, and supporting investments across medical devices, clinical technologies, and...
by Laura Rinaldi | May 29, 2026 | Blog, Why We Invested
By: Scott Button, Partner at Clarevia Ventures RiverMark Medical recently announced a $20 million Series D financing led by Andera Partners to develop the FloStent™ System, an investigational device designed to offer a non-surgical, reversible, office-based treatment...
by North Woods | May 6, 2026 | Blog, Firm News
MADISON, Wis., May 6, 2026 — Venture Investors Health Fund, one of the Midwest’s longest-standing healthcare-focused venture firms, today announced its rebrand to Clarevia Ventures, a new name that reflects the firm’s sharpened focus on helping early-stage medtech and...
by North Woods | Mar 24, 2026 | Blog, Perspectives
By Jenni Le, Principal, Clarevia A patient suspected of sleep apnea used to spend the night in a lab, hooked up to sensors, trying to sleep in an unfamiliar environment, often producing a poor representation of a typical night. Today, that same patient can sleep in...
by North Woods | Mar 4, 2026 | Blog, Perspectives
By Paul Weiss, PhD, Partner at Clarevia In breast cancer, there was a moment when outcomes changed dramatically, but only for certain patients. Herceptin, an antibody therapy, was developed to target an overexpression of the HER2 protein. If a patient was...
by North Woods | Jan 20, 2026 | Blog, Portfolio Spotlights
For millions of people living with glaucoma, treatment often begins with a familiar daily routine: prescription eye drops lined up on the bathroom counter, reminders taped to mirrors, and the quiet worry that missing a dose could allow the disease to progress. As...
